Control of colon cancer development and progression by selected estrogen receptor modulators

Estrogens behave as protective agents on the development of colorectal cancer, and hormonal-replacement therapy is associated with an increased survival rate in women with this disease, indicating that estrogenic therapy correlates with a better prognosis. The protective effect of estrogens on Fcolorectal cancer development and progression is presumably related to the expression of estrogen receptors in colon mucosa, with the estrogen receptor-β isoform being the predominant one. This observation suggests that estrogen receptor-β could have an inhibitory effect on colorectal cancer cell proliferation and a regulatory effect on colonic mucosa cell growth, opening the discussion on a pharmacologic approach to colorectal cancer prevention and therapy based on estrogenic compounds.

[1]  X. Zhang,et al.  AP-2 regulates the transcription of estrogen receptor (ER)-β by acting through a methylation hotspot of the 0N promoter in prostate cancer cells , 2007, Oncogene.

[2]  R. Labianca,et al.  Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer , 2007, Expert review of anticancer therapy.

[3]  E. Barrett-Connor,et al.  Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.

[4]  Rakesh Kumar,et al.  Signaling regulation of genomic and nongenomic functions of estrogen receptors. , 2006, Cancer letters.

[5]  H. Morreau,et al.  Diagnostic Approach and Management of Lynch Syndrome (Hereditary Nonpolyposis Colorectal Carcinoma): A Guide for Clinicians , 2006, CA: a cancer journal for clinicians.

[6]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[7]  Shin-Da Lee,et al.  Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. , 2006, The Chinese journal of physiology.

[8]  J. Gustafsson,et al.  Role of estrogen receptor β in colonic epithelium , 2006 .

[9]  S. Cummings,et al.  Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  V. Speirs,et al.  Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. , 2005, Oncology reports.

[11]  A. Gozzini,et al.  ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. , 2005, Endocrine-related cancer.

[12]  H C van Houwelingen,et al.  Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment , 2005, Journal of Medical Genetics.

[13]  D. Grady,et al.  Raloxifene and colorectal cancer. , 2005, Journal of women's health.

[14]  Margaret Warner,et al.  Reflections on the Discovery and Significance of Estrogen Receptor (cid:1) , 2005 .

[15]  Jian-Hua Wang,et al.  Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo. , 2005, World journal of gastroenterology.

[16]  G. Greene,et al.  Plasma membrane estrogen receptors exist and functions as dimers. , 2004, Molecular endocrinology.

[17]  S. Cummings,et al.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. , 2004, Journal of the National Cancer Institute.

[18]  J. Cauley,et al.  Risk‐Benefit Profile for Raloxifene: 4‐Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  Haiyan Yang,et al.  Clinical relationship between MDR1 gene and gallbladder cancer. , 2004, Hepatobiliary & pancreatic diseases international : HBPD INT.

[20]  R. Chlebowski,et al.  Estrogen plus progestin and colorectal cancer in postmenopausal women. , 2004, The New England journal of medicine.

[21]  Jie-ping Yu,et al.  Expression of estrogen receptor beta in human colorectal cancer. , 2004, World journal of gastroenterology.

[22]  J. Potter,et al.  Hormone replacement therapy in relation to survival in women diagnosed with colon cancer , 2003, Cancer Causes & Control.

[23]  E. Lam,et al.  Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. , 2003, Oncogene.

[24]  D. Schuppan,et al.  Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells. , 2003, International journal of oncology.

[25]  O. Johnell,et al.  Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. , 2003, Bone.

[26]  A. Papavassiliou,et al.  Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. , 2003, European journal of cancer.

[27]  M. Brandi,et al.  Growth response of colon cancer cell lines to selective estrogen receptor modulators. , 2003, Anticancer research.

[28]  Shen-Liang Chen,et al.  Mitogen-activated protein kinases potentiate thyroid hormone receptor transcriptional activity by stabilizing its protein. , 2003, Endocrinology.

[29]  S. Olschwang,et al.  Cancer risk in 348 French MSH2 or MLH1 gene carriers , 2003, Journal of medical genetics.

[30]  A. Miller,et al.  Obesity and colorectal cancer risk in women , 2002, Gut.

[31]  W. Bai,et al.  Regulation of Estrogen Receptor Nuclear Export by Ligand-Induced and p38-Mediated Receptor Phosphorylation , 2002, Molecular and Cellular Biology.

[32]  Chris Albanese,et al.  Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression* , 2002, The Journal of Biological Chemistry.

[33]  Richard G. W. Anderson,et al.  ERβ Has Nongenomic Action in Caveolae , 2002 .

[34]  Alison L. Livingston,et al.  Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors , 2002, Nature Genetics.

[35]  S. Cummings,et al.  Serum estradiol level and risk of breast cancer during treatment with raloxifene. , 2002, JAMA.

[36]  James H. Segars,et al.  The Proto-oncoprotein Brx Activates Estrogen Receptor β by a p38 Mitogen-activated Protein Kinase Pathway* , 2001, The Journal of Biological Chemistry.

[37]  L. Norton,et al.  The MORE Trial: Multiple Outcomes for Raloxifene Evaluation , 2001, Annals of the New York Academy of Sciences.

[38]  E. Giovannucci.  Insulin, insulin-like growth factors and colon cancer: a review of the evidence. , 2001, The Journal of nutrition.

[39]  R. Dahiya,et al.  CpG hypermethylation of the promoter region inactivates the estrogen receptor‐β gene in patients with prostate carcinoma , 2001, Cancer.

[40]  P. Møller,et al.  MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Toru Watanabe,et al.  Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance , 2001, Anti-cancer drugs.

[42]  L. Andersson,et al.  A role for estrogen receptor β in the regulation of growth of the ventral prostate , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Buchert,et al.  In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  M. Bertagnolli,et al.  Reciprocal Expression of ERα and ERβ Is Associated with Estrogen-mediated Modulation of Intestinal Tumorigenesis , 2001 .

[45]  J. Thomsen,et al.  Mechanisms of estrogen action. , 2001, Physiological reviews.

[46]  H. Sakamoto,et al.  Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. , 2000, Cancer letters.

[47]  S. Nicosia,et al.  MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. , 2000, Molecular endocrinology.

[48]  J. Gustafsson,et al.  Estrogen receptor β acts as a dominant regulator of estrogen signaling , 2000, Oncogene.

[49]  J. Gustafsson,et al.  Estrogen receptor beta mRNA in colon cancer cells: growth effects of estrogen and genistein. , 2000, Biochemical and biophysical research communications.

[50]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[51]  M. Brandi,et al.  Functional Estrogen Receptor in Colon Cancer Cells , 1999 .

[52]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[53]  K. Korach,et al.  Estrogen receptor null mice: what have we learned and where will they lead us? , 1999, Endocrine reviews.

[54]  F. Grodstein,et al.  Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. , 1999, The American journal of medicine.

[55]  L. Aaltonen,et al.  Cancer risk in mutation carriers of DNA‐mismatch‐repair genes , 1999, International journal of cancer.

[56]  J. Corton,et al.  Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β. , 1998, Endocrinology.

[57]  G. Colditz,et al.  Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. , 1998, Journal of the National Cancer Institute.

[58]  G. Colditz,et al.  Postmenopausal Hormone Use and Risk for Colorectal Cancer and Adenoma , 1998, Annals of Internal Medicine.

[59]  Bert Vogelstein,et al.  Gatekeepers and caretakers , 1997, Nature.

[60]  L. Aaltonen,et al.  Life‐time risk of different cancers in hereditary non‐polyposis colorectal cancer (hnpcc) syndrome , 1995, International journal of cancer.

[61]  C. Paraskeva,et al.  Differential growth response to oestrogen of premalignant and malignant colonic cell lines. , 1994, Anticancer research.

[62]  M. Riegler,et al.  The multidrug-resistance modifiers verapamil, cyclosporine A and tamoxifen induce an intracellular acidification in colon carcinoma cell lines in vitro. , 1993, Anticancer research.

[63]  J. Weber,et al.  Genetic mapping of a locus predisposing to human colorectal cancer. , 1993, Science.

[64]  S. Narayan,et al.  Estradiol is trophic for colon cancer in mice: effect on ornithine decarboxylase and c-myc messenger RNA. , 1992, Gastroenterology.

[65]  B. Ponder,et al.  Molecular Genetics of Cancer , 1992, Nature Medicine.

[66]  D. Powell,et al.  Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. , 1991, The Journal of biological chemistry.

[67]  J. Bishop.  Molecular themes in oncogenesis , 1991, Cell.

[68]  Kathleen R. Cho,et al.  Identification of a chromosome 18q gene that is altered in colorectal cancers. , 1990, Science.

[69]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[70]  F. C. Lucibello,et al.  Localization of the gene for familial adenomatous polyposis on chromosome 5 , 1987, Nature.

[71]  Ona Fv,et al.  Gallbladder disease: risk factor for colorectal carcinoma? , 1984 .

[72]  J. Potter,et al.  Do intrinsic sex differences in lower alimentary tract physiology influence the sex-specific risks of bowel cancer and other biliary and intestinal diseases? , 1983, American journal of epidemiology.

[73]  W. Chow,et al.  Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. , 1981, Journal of the National Cancer Institute.

[74]  J. Potter,et al.  Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. , 1980, Journal of the National Cancer Institute.

[75]  L. Happerfield,et al.  Interpretation of Immunohistochemical Analysis of MisMatch Repair (MMR) Protein Expression in Tissue Sections for Investigation of Suspected Lynch / Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Syndrome , 2008 .

[76]  Jie-PingYu,et al.  Expression of estrogen receptor β in human colorectal cancer , 2004 .

[77]  T. Powles,et al.  Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial , 2004, Breast Cancer Research and Treatment.

[78]  H. Lynch,et al.  Cancer risk in mismatch repair gene mutation carriers , 2004, Familial Cancer.

[79]  D. Fan,et al.  Expression of cDNA fragment encoding MGr1-Ag1 detected by MDR related antibody MGr1 in gastric cancer , 2003 .

[80]  Chris Albanese,et al.  Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. , 2002, The Journal of biological chemistry.

[81]  J. Potter,et al.  Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. , 2001, Cancer research.

[82]  I. J. Lynch,et al.  Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. , 2001, Cancer research.

[83]  J. Gustafsson,et al.  Role of estrogen receptor beta in estrogen action. , 2001, Annual review of physiology.

[84]  K. Kinzler,et al.  Cancer-susceptibility genes. Gatekeepers and caretakers. , 1997, Nature.

[85]  F. Ona,et al.  Gallbladder disease: risk factor for colorectal carcinoma? , 1984, Journal of clinical gastroenterology.

[86]  M. Roberfroid,et al.  Mutagenicity of 1,2-dimethylhydrazine towards Salmonella typhimurium, co-mutagenic effect of secondary biliary acids. , 1983, Carcinogenesis.